
Please try another search
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
Name | Age | Since | Title |
---|---|---|---|
Thomas Henderson | 59 | 2012 | Co-Founder & Non-Executive Director |
Nicholas David Moss | 66 | 2012 | Senior Independent Director |
Nigel John Keen | 78 | 2016 | Non-Executive Director |
Robert Anthony Hutchinson | - | 2017 | Non-Executive Director |
Gian Piero Reverberi | 59 | 2018 | Non-Executive Director |
Kemal Malik | 63 | 2020 | Non-Executive Director |
Virginia Anne Holmes | 65 | 2021 | Non-Executive Director |
Kenneth H. Galbraith | 62 | 2023 | Chair of SIML & Executive Partner |
Cristina Csimma | 66 | 2022 | Non-Executive Director |
Julie Michele Cherrington | 67 | - | Non-Executive Director |
John Roche | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review